JAC Advance Access published online on June 12, 2003
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkg280
© 2003 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Brief report
1 Clinical Microbiology,
Central Hospital, S-351 85 Växjö, Sweden
* Corresponding author. E-mail: gunnar.kahlmeter{at}ltkronoberg.se.
Received 27 December 2002
; revised 2 April 2003
; accepted 2 April 2003
The antimicrobial resistance profiles, comprising 12
antibiotics, of 2478 isolates of Escherichia coli from
the ECO·SENS Project involving women with acute uncomplicated
urinary tract infection at 252 community health care centres in
17 countries were determined. Resistance to ampicillin alone (6.3%)
and sulfamethoxazole alone (5.4%) were the most common ‘single
resistances'. Multiple resistance was most common in Spain
and least common in Finland. The main associated-resistance profiles
involved ampicillin/sulfamethoxazole (8.7%) and ampicillin/sulfamethoxazole/trimethoprim/trimethoprim-sulfamethoxazole (6.4%).
The most common profile of multiple resistance was ampicillin/sulfamethoxazole/trimethoprim/trimethoprim-sulfamethoxazole/nalidixic
acid/ciprofloxacin. Twenty-one isolates, half of which came from Spain,
were resistant to seven antibiotics or more. Three isolates, one
from Spain and two from Portugal, were resistant to nine of the
12 antibiotics investigated.
Keywords: cross-resistance, associated resistance, Escherichia
coli
Cross-resistance and associated resistance in 2478 Escherichia coli isolates from the Pan-European
ECO·SENS Project surveying the antimicrobial susceptibility
of pathogens from uncomplicated urinary tract infections
2 LEO Pharma, DK-2750 Ballerup, Denmark
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Sundqvist, P. Geli, D. I. Andersson, M. Sjolund-Karlsson, A. Runehagen, H. Cars, K. Abelson-Storby, O. Cars, and G. Kahlmeter Little evidence for reversibility of trimethoprim resistance after a drastic reduction in trimethoprim use J. Antimicrob. Chemother., November 8, 2009; (2009) dkp387v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sundqvist and G. Kahlmeter 'Pre-emptive culturing' will improve the chance of 'getting it right' when empirical therapy of urinary tract infections fails J. Antimicrob. Chemother., August 1, 2009; 64(2): 227 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Takahashi, T. Muratani, M. Yasuda, S. Takahashi, K. Monden, K. Ishikawa, H. Kiyota, S. Arakawa, T. Matsumoto, H. Shima, et al. Genetic Profiles of Fluoroquinolone-Resistant Escherichia coli Isolates Obtained from Patients with Cystitis: Phylogeny, Virulence Factors, PAIusp Subtypes, and Mutation Patterns J. Clin. Microbiol., March 1, 2009; 47(3): 791 - 795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Uzunovic-Kamberovic Antibiotic resistance of coliform organisms from community-acquired urinary tract infections in Zenica-Doboj Canton, Bosnia and Herzegovina J. Antimicrob. Chemother., August 1, 2006; 58(2): 344 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Landgren, H. Oden, I. Kuhn, A. Osterlund, and G. Kahlmeter Diversity among 2481 Escherichia coli from women with community-acquired lower urinary tract infections in 17 countries J. Antimicrob. Chemother., June 1, 2005; 55(6): 928 - 937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Kahlmeter, P. Menday, and O. Cars Non-hospital antimicrobial usage and resistance in community-acquired Escherichia coli urinary tract infection J. Antimicrob. Chemother., December 1, 2003; 52(6): 1005 - 1010. [Abstract] [Full Text] [PDF]
|
|